Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?

Tuberculosis

Volumn 93, Issue 6, 2013, Pages 569-588

  Goldman, Robert C ^a  

^a RCG Consulting   (United States)

Author keywords

Antitubercular drugs; Genetic analysis; High throughput screening; Hydrophobic compounds; Membrane targets

Indexed keywords

7 BROMO 2 METHYL 5 NITRO 3 PHENYLQUINOXALINE; ATPE PROTEIN; AU 1235; BEDAQUILINE; BENZIMIDAZOLE; CYCLOSERINE; DAPTOMYCIN; DPRE PROTEIN; ETHAMBUTOL; GLPK PROTEIN; GRAMICIDIN S; GROWTH INHIBITOR; IMIDAZOLE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; LINEZOLID; LIPID; MEMBRANE PROTEIN; MMPL3 PROTEIN; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PKS13 PROTEIN; PYRAZINAMIDE; PYRIMIDINE; QCRB PROTEIN; STREPTOMYCIN; TELAVANCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VI 18469;

BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CALCULATION; DRUG TARGETING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HYDROPHOBICITY; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; TUBERCULOSIS;

ANTITUBERCULAR DRUGS; GENETIC ANALYSIS; HIGH THROUGHPUT SCREENING; HYDROPHOBIC COMPOUNDS; MEMBRANE TARGETS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG DISCOVERY; GENOME, BACTERIAL; HIGH-THROUGHPUT SCREENING ASSAYS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; SMALL MOLECULE LIBRARIES;

EID: 84887406804     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2013.09.003     Document Type: Review

References (193)

1. Z.F. Udwadia, R.A. Amale, K.K. Ajbani, and C. Rodrigues Totally drug-resistant tuberculosis in India Clin Infect Dis Off Pub of the Infect Dis Soc Am 54 2012 579 581 10.1093/cid/cir889
2. M. Klopper, R. Warren, C. Hayes, N. van Pittius, E. Streicher, and B. Müller Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa Emerg Infect Dis [Internet] 19 2013
3. R.C. Goldman, K.V. Plumley, and B.E. Laughon The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control Infect Disord Drug Targets 7 2007 73 91
4. J. Engohang-Ndong Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment Expert Opin Investig Drugs 21 2012 1789 1800 10.1517/13543784.2012.724397
5. A. Bocker, P.R. Bonneau, and P.J. Edwards HTS promiscuity analyses for accelerating decision making J Biomol Screen 16 2011 765 774 10.1177/1087057111407763
6. T.J. Crisman, C.N. Parker, J.L. Jenkins, J. Scheiber, M. Thoma, and Z.B. Kang Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data J Chem Inf Model 47 2007 1319 1327 10.1021/ci6005504
7. B.Y. Feng, A. Shelat, T.N. Doman, R.K. Guy, and B.K. Shoichet High-throughput assays for promiscuous inhibitors Nat Chem Biol 1 2005 146 148 10.1038/nchembio718
8. A. Jadhav, R.S. Ferreira, C. Klumpp, B.T. Mott, C.P. Austin, and J. Inglese Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease J Med Chem 53 2010 37 51 10.1021/jm901070c
9. S.L. McGovern, E. Caselli, N. Grigorieff, and B.K. Shoichet A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening J Med Chem 45 2002 1712 1722
10. J.T. Metz, J.R. Huth, and P.J. Hajduk Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups J Comput-Aided Mol Des 21 2007 139 144 10.1007/s10822-007-9109-z
11. 2 by redox cycling in reducing environments Assay Drug Develop Technol 8 2010 152 174 10.1089/adt.2009.0247
12. J. Wolcke, N. Hunt, J. Jungmann, and D. Ullmann Early identification of false positives in high-throughput screening for activators of p53-DNA interaction J Biomol Screen 11 2006 341 350 10.1177/1087057106286652
13. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 46 2001 3 26
14. L.M. Jarvis Rethinking TB drugs Chem Eng News 90 2012
15. S. Ananthan, E.R. Faaleolea, R.C. Goldman, J.V. Hobrath, C.D. Kwong, and B.E. Laughon High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv Tuberculosis 89 2009 334 353 10.1016/j.tube.2009.05.008
16. P. Brodin, Y. Poquet, F. Levillain, I. Peguillet, G. Larrouy-Maumus, and M. Gilleron High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling PLoS Pathogens 6 2010 e1001100 10.1371/journal.ppat.1001100
17. T. Christophe, M. Jackson, H.K. Jeon, D. Fenistein, M. Contreras-Dominguez, and J. Kim High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors PLoS Pathogens 5 2009 e1000645 10.1371/journal. ppat.1000645
18. M. Flipo, N. Willand, N. Lecat-Guillet, C. Hounsou, M. Desroses, and F. Leroux Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis J Med Chem 55 2012 6391 6402 10.1021/jm300377g
19. A. Kumar, M. Zhang, L. Zhu, R.P. Liao, C. Mutai, and S. Hafsat High-throughput screening and sensitized bacteria identify an M tuberculosis dihydrofolate reductase inhibitor with whole cell activity PloS One 7 2012 e39961 10.1371/journal.pone.0039961
20. J.A. Maddry, S. Ananthan, R.C. Goldman, J.V. Hobrath, C.D. Kwong, and C. Maddox Antituberculosis activity of the molecular libraries screening center network library Tuberculosis 89 2009 354 363 10.1016/j.tube.2009.07.006
21. R.C. Reynolds, S. Ananthan, E. Faaleolea, J.V. Hobrath, C.D. Kwong, and C. Maddox High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv Tuberculosis 92 2012 72 83 10.1016/j.tube.2011.05.005
22. S.A. Stanley, S.S. Grant, T. Kawate, N. Iwase, M. Shimizu, and C. Wivagg Identification of novel inhibitors of M tuberculosis growth using whole cell based high-throughput screening ACS Chem Biol 7 2012 1377 1384 10.1021/cb300151m
23. K. Pethe, P.C. Sequeira, S. Agarwalla, K. Rhee, K. Kuhen, and W.Y. Phong A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy Nat Commun 1 2010 57 10.1038/ncomms1060
24. S. Magnet, R.C. Hartkoorn, R. Szekely, J. Pato, J.A. Triccas, and P. Schneider Leads for antitubercular compounds from kinase inhibitor library screens Tuberculosis 90 2010 354 360 10.1016/j.tube.2010.09.001
25. R.T. Voegele, G.D. Sweet, and W. Boos Glycerol kinase of Escherichia coli is activated by interaction with the glycerol facilitator J Bacteriol 175 1993 1087 1094
26. N.A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernas, and A.S. Hussain Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol Pharm 1 2004 85 96
27. K. Andries, P. Verhasselt, J. Guillemont, H.W. Gohlmann, J.M. Neefs, and H. Winkler A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227 10.1126/science.1106753
28. S. Petrella, E. Cambau, A. Chauffour, K. Andries, V. Jarlier, and W. Sougakoff Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria Antimicrobial Agents Chemother 50 2006 2853 2856 10.1128/AAC.00244-06
29. A.C. Haagsma, R. Abdillahi-Ibrahim, M.J. Wagner, K. Krab, K. Vergauwen, and J. Guillemont Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue Antimicrobial Agents Chemother 53 2009 1290 1292 10.1128/AAC.01393-08
30. A.C. Haagsma, I. Podasca, A. Koul, K. Andries, J. Guillemont, and H. Lill Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase PloS One 6 2011 e23575 10.1371/journal.pone.0023575
31. A. Koul, L. Vranckx, N. Dendouga, W. Balemans, I. Van den Wyngaert, and K. Vergauwen Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis J Biol Chem 283 2008 25273 25280 10.1074/jbc.M803899200
32. M. Altaf, C.H. Miller, D.S. Bellows, and R. O'Toole Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors Tuberculosis 90 2010 333 337 10.1016/j.tube.2010.09.002
33. S.T. Cole, and G. Riccardi New tuberculosis drugs on the horizon Curr Opin Microbiol 14 2011 570 576 10.1016/j.mib.2011.07.022
34. G. Manina, M.R. Pasca, S. Buroni, E. De Rossi, and G. Riccardi Decaprenylphosphoryl-beta-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target Curr Med Chem 17 2010 3099 3108
35. J.E. Griffin, J.D. Gawronski, M.A. Dejesus, T.R. Ioerger, B.J. Akerley, and C.M. Sassetti High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism PLoS Pathogens 7 2011 e1002251 10.1371/journal.ppat.1002251
36. P.K. Crellin, R. Brammananth, and R.L. Coppel Decaprenylphosphoryl-beta- D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis PloS One 6 2011 e16869 10.1371/journal.pone.0016869
37. G.A. de Souza, N.A. Leversen, H. Malen, and H.G. Wiker Bacterial proteins with cleaved or uncleaved signal peptides of the general secretory pathway J Proteomics 75 2011 502 510 10.1016/j.jprot.2011.08.016
38. S. Gu, J. Chen, K.M. Dobos, E.M. Bradbury, J.T. Belisle, and X. Chen Comprehensive proteomic profiling of the membrane constituents of a Mycobacterium tuberculosis strain Mol Cell Proteomics: MCP 2 2003 1284 1296 10.1074/mcp.M300060-MCP200
39. H. Malen, S. Pathak, T. Softeland, G.A. de Souza, and H.G. Wiker Definition of novel cell envelope associated proteins in Triton X-114 extracts of Mycobacterium tuberculosis H37Rv BMC Microbiol 10 2010 132 10.1186/1471-2180-10-132
40. K.G. Mawuenyega, C.V. Forst, K.M. Dobos, J.T. Belisle, J. Chen, and E.M. Bradbury Mycobacterium tuberculosis functional network analysis by global subcellular protein profiling Mol Biol Cell 16 2005 396 404 10.1091/mbc.E04-04- 0329
41. V. Makarov, G. Manina, K. Mikusova, U. Mollmann, O. Ryabova, and B. Saint-Joanis Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis Science 324 2009 801 804 10.1126/science.1171583
42. G. Manina, M. Bellinzoni, M.R. Pasca, J. Neres, A. Milano, and A.L. Ribeiro Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance Mol Microbiol 77 2010 1172 1185 10.1111/j.1365-2958.2010.07277.x
43. A.L. Ribeiro, G. Degiacomi, F. Ewann, S. Buroni, M.L. Incandela, and L.R. Chiarelli Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis PloS One 6 2011 e26675 10.1371/journal.pone.0026675
44. C. Trefzer, M. Rengifo-Gonzalez, M.J. Hinner, P. Schneider, V. Makarov, and S.T. Cole Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-beta-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis J Am Chem Soc 132 2010 13663 13665 10.1021/ja106357w
45. H. Li, and G. Jogl Crystal structure of decaprenylphosphoryl-beta- D-ribose 2'-epimerase from Mycobacterium smegmatis Proteins 81 2013 538 543 10.1002/prot.24220
46. S.M. Batt, T. Jabeen, V. Bhowruth, L. Quill, P.A. Lund, and L. Eggeling Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors Proc Natl Acad Sci USA 109 2012 11354 11359 10.1073/pnas.1205735109
47. J. Neres, F. Pojer, E. Molteni, L.R. Chiarelli, N. Dhar, and S. Boy-Rottger Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis Science Transl Med 4 2012 10.1126/scitranslmed. 3004395 150ra121
48. R.C. Goldman, and B.E. Laughon Discovery and validation of new antitubercular compounds as potential drug leads and probes Tuberculosis 89 2009 331 333 10.1016/j.tube.2009.07.007
49. A.E. Grzegorzewicz, H. Pham, V.A. Gundi, M.S. Scherman, E.J. North, and T. Hess Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane Nat Chem Biol 8 2012 334 341 10.1038/nchembio.794
50. V. La Rosa, G. Poce, J.O. Canseco, S. Buroni, M.R. Pasca, and M. Biava MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212 Antimicrobial Agents Chemother 56 2012 324 331 10.1128/AAC.05270-11
51. M.S. Scherman, E.J. North, V. Jones, T.N. Hess, A.E. Grzegorzewicz, and T. Kasagami Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability Bioorg Med Chem 20 2012 3255 3262 10.1016/j.bmc.2012.03.058
52. K. Tahlan, R. Wilson, D.B. Kastrinsky, K. Arora, V. Nair, and E. Fischer SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis Antimicrobial Agents Chemother 56 2012 1797 1809 10.1128/AAC.05708-11
53. C. Varela, D. Rittmann, A. Singh, K. Krumbach, K. Bhatt, and L. Eggeling MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria Chem Biol 19 2012 498 506 10.1016/j.chembiol.2012.03.006
54. D. Deidda, G. Lampis, R. Fioravanti, M. Biava, G.C. Porretta, and S. Zanetti Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains Antimicrobial Agents Chemother 42 1998 3035 3037
55. P. Domenech, M.B. Reed, and C.E. Barry III Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance Infect Immun 73 2005 3492 3501 10.1128/IAI.73.6.3492-3501.2005
56. G. Poce, R.H. Bates, S. Alfonso, M. Cocozza, G.C. Porretta, and L. Ballell Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute Murine model of tuberculosis infection PloS One 8 2013 e56980 10.1371/journal.pone. 0056980
57. E.J. North, M.S. Scherman, D.F. Bruhn, J.S. Scarborough, M.M. Maddox, and V. Jones Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties Bioorg Med Chem 21 2013 2587 2599 10.1016/j.bmc.2013.02.028
58. J. Liu, D. Obando, V. Liao, T. Lifa, and R. Codd The many faces of the adamantyl group in drug design Eur J Med Chem 46 2011 1949 1963 10.1016/j.ejmech.2011.01.047
59. G. Lamoureux, and G. Artavia Use of the adamantane structure in medicinal chemistry Curr Med Chem 17 2010 2967 2978
60. D. Alland, A.J. Steyn, T. Weisbrod, K. Aldrich, and W.R. Jacobs Jr. Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition J Bacteriol 182 2000 1802 1811
61. M.J. Remuinan, E. Perez-Herran, J. Rullas, C. Alemparte, M. Martinez-Hoyos, D.J. Dow L. Ballell, and N. Cammack Tetrahydropyrazolo[1,5-a] pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'- thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3 PloS One 8 2013 e60933 10.1371/journal.pone.0060933
62. L. Ballell, R.H. Bates, R.J. Young, D. Alvarez-Gomez, E. Alvarez-Ruiz, and V. Barroso Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis ChemMedChem 8 2013 313 321 10.1002/cmdc.201200428
63. O.K. Onajole, M. Pieroni, S.K. Tipparaju, S. Lun, J. Stec, and G. Chen Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains J Med Chem 56 2013 4093 4103 10.1021/jm4003878
64. K.A. Abrahams, J.A. Cox, V.L. Spivey, N.J. Loman, M.J. Pallen, and C. Constantinidou Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M tuberculosis QcrB PloS One 7 2012 e52951 10.1371/journal.pone. 0052951
65. C.M. Sassetti, D.H. Boyd, and E.J. Rubin Comprehensive identification of conditionally essential genes in mycobacteria Proc Natl Acad Sci USA 98 2001 12712 12717 10.1073/pnas.231275498
66. C.M. Sassetti, D.H. Boyd, and E.J. Rubin Genes required for mycobacterial growth defined by high density mutagenesis Mol Microbiol 48 2003 77 84
67. K. Pethe, P. Bifani, J. Jang, S. Kang, S. Park, and S. Ahn Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis Nat Med 2013 10.1038/nm.3262
68. M.K. Tokito, and F. Daldal Roles in inhibitor recognition and quinol oxidation of the amino acid side chains at positions of cyt b providing resistance to Qo-inhibitors of the bc1 complex from Rhodobacter capsulatus Mol Microbiol 9 1993 965 978
69. S. Gavalda, M. Leger, B. van der Rest, A. Stella, F. Bardou, and H. Montrozier The Pks13/FadD32 crosstalk for the biosynthesis of mycolic acids in Mycobacterium tuberculosis J Biol Chem 284 2009 19255 19264 10.1074/jbc.M109. 006940
70. D. Portevin, C. De Sousa-D'Auria, C. Houssin, C. Grimaldi, M. Chami, and M. Daffe A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms Proc Natl Acad Sci USA 101 2004 314 319 10.1073/pnas.0305439101
71. P. Carroll, M.C. Faray-Kele, and T. Parish Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach Appl Environ Microbiol 77 2011 5040 5043 10.1128/AEM.02880-10
72. R. Wilson, P. Kumar, V. Parashar, C. Vilcheze, R. Veyron-Churlet, and J.S. Freundlich Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis Nat Chem Biol 9 2013 499 506 10.1038/nchembio.1277
73. A. Whitty Cooperativity and biological complexity Nat Chem Biol 4 2008 435 439 10.1038/nchembio0808-435
74. G. Adams, and M. Delbruck Reduction of dimensionality in biological diffusion processes A. Rich, N. Davidson, Structural chemistry and molecular biology San Francisco 1968 W.H. Freeman and Company London 198 215
75. L. Herbette, F.C. Messineo, and A.M. Katz The interaction of drugs with the sarcoplasmic reticulum Ann Rev Pharmacol Toxicol 22 1982 413 434 10.1146/annurev.pa.22.040182.002213
76. J.K. Blasie, J.M. Pachence, and L.G. Herbette Neutron diffraction and the decomposition of membrane scattering profiles into the scattering profiles of their molecular components Basic Life Sci 27 1984 201 210
77. L. Herbette, C.A. Napolitano, F.C. Messineo, and A.M. Katz Interaction of amphiphilic molecules with biological membranes. A model for nonspecific and specific drug effects with membranes Adv Myocardiol 5 1985 333 346
78. D.G. Rhodes, J.G. Sarmiento, and L.G. Herbette Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site Mol Pharmacol 27 1985 612 623
79. D.W. Chester, L.G. Herbette, R.P. Mason, A.F. Joslyn, D.J. Triggle, and D.E. Koppel Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers Biophys J 52 1987 1021 1030 10.1016/S0006- 3495(87)83295-2
80. L.G. Herbette, Y.M. Vant Erve, and D.G. Rhodes Interaction of 1,4 dihydropyridine calcium channel antagonists with biological membranes: lipid bilayer partitioning could occur before drug binding to receptors J Mol Cell Cardiol 21 1989 187 201
81. R.P. Mason, S.F. Campbell, S.D. Wang, and L.G. Herbette Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes Mol Pharmacol 36 1989 634 640
82. L.G. Herbette, D.G. Rhodes, and R.P. Mason New approaches to drug design and delivery based on drug-membrane interactions Drug Des Deliv 7 1991 75 118
83. L. Herbette, P. DeFoor, S. Fleischer, D. Pascolini, A. Scarpa, and J.K. Blasie The separate profile structures of the functional calcium pump protein and the phospholipid bilayer within isolated sarcoplasmic reticulum membranes determined by X-ray and neutron diffraction Biochim et Biophys Acta 817 1985 103 122
84. L.G. Herbette, G. Gaviraghi, T. Tulenko, and R.P. Mason Molecular interaction between lacidipine and biological membranes J Hypertens Suppl Off J Inter Soc Hypertens 11 1993 S13 S19
85. L.G. Herbette, P.E. Mason, G. Gaviraghi, T.N. Tulenko, and R.P. Mason The molecular basis for lacidipine's unique pharmacokinetics: optimal hydrophobicity results in membrane interactions that may facilitate the treatment of atherosclerosis J Cardiovasc Pharmacol 23 Suppl. 5 1994 S16 S25
86. L.G. Herbette, P.E. Mason, K.R. Sweeney, M.W. Trumbore, and R.P. Mason Favorable amphiphilicity of nimodipine facilitates its interactions with brain membranes Neuropharmacology 33 1994 241 249
87. L.G. Herbette, M. Trumbore, D.W. Chester, and A.M. Katz Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone J Mol Cell Cardiol 20 1988 373 378
88. E. Varga, J. Szollosi, K. Antal, P. Kovacs, and J.Z. Szabo Nonspecific membrane effects of CH-103: hydrophobicity, surface activity and membrane fluidity studies in comparison with propranolol and practolol Die Pharmazie 54 1999 380 384
89. M.J. Sykes, M.J. Sorich, and J.O. Miners Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes J Chem Inform Model 46 2006 2661 2673 10.1021/ci600221h
90. L. Zhao, and S.S. Feng Effects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes J Colloid Interface Sci 274 2004 55 68 10.1016/j.jcis.2003.12.009
91. L. Adamian, H. Naveed, and J. Liang Lipid-binding surfaces of membrane proteins: evidence from evolutionary and structural analysis Biochim et Biophys Acta 1808 2011 1092 1102 10.1016/j.bbamem.2010.12.008
92. A.G. Lee How lipids and proteins interact in a membrane: a molecular approach Mol BioSystems 1 2005 203 212 10.1039/b504527d
93. S. Galdiero, M. Galdiero, and C. Pedone beta-Barrel membrane bacterial proteins: structure, function, assembly and interaction with lipids Curr Protein Pept Sci 8 2007 63 82
94. T. Pali, D. Bashtovyy, and D. Marsh Stoichiometry of lipid interactions with transmembrane proteins-Deduced from the 3D structures Protein Sci Pub Protein Soc 15 2006 1153 1161 10.1110/ps.052021406
95. M. Iwamoto, and S. Oiki Amphipathic antenna of an inward rectifier K+ channel responds to changes in the inner membrane leaflet Proc Natl Acad Sci USA 110 2013 749 754 10.1073/pnas.1217323110
96. M. Raja The potassium channel KcsA: a model protein in studying membrane protein oligomerization and stability of oligomeric assembly? Arch Biochem Biophys 510 2011 1 10 10.1016/j.abb.2011.03.010
97. M. Weingarth, A. Prokofyev, E.A. van der Cruijsen, D. Nand, A.M. Bonvin, and O. Pongs Structural determinants of specific lipid binding to potassium channels J Am Chem Soc 135 2013 3983 3988 10.1021/ja3119114
98. S.S. Deol, P.J. Bond, C. Domene, and M.S. Sansom Lipid-protein interactions of integral membrane proteins: a comparative simulation study Biophys J 87 2004 3737 3749 10.1529/biophysj.104.048397
99. M.S. Sansom, P.J. Bond, S.S. Deol, A. Grottesi, S. Haider, and Z.A. Sands Molecular simulations and lipid-protein interactions: potassium channels and other membrane proteins Biochem Soc Trans 33 2005 916 920 10.1042/BST20050916
100. I.M. Williamson, S.J. Alvis, J.M. East, and A.G. Lee The potassium channel KcsA and its interaction with the lipid bilayer Cell Mol Life Sci CMLS 60 2003 1581 1590 10.1007/s00018-003-3172-y
101. A.M. Powl, J. Carney, P. Marius, J.M. East, and A.G. Lee Lipid interactions with bacterial channels: fluorescence studies Biochem Soc Trans 33 2005 905 909 10.1042/BST20050905
102. A.M. Powl, J.M. East, and A.G. Lee Heterogeneity in the binding of lipid molecules to the surface of a membrane protein: hot spots for anionic lipids on the mechanosensitive channel of large conductance MscL and effects on conformation Biochemistry 44 2005 5873 5883 10.1021/bi047439e
103. J. Carney, J.M. East, and A.G. Lee Penetration of lipid chains into transmembrane surfaces of membrane proteins: studies with MscL Biophys J 92 2007 3556 3563 10.1529/biophysj.106.102210
104. E.J. Prenner, R.N. Lewis, and R.N. McElhaney The interaction of the antimicrobial peptide gramicidin S with lipid bilayer model and biological membranes Biochim et Biophys Acta 1462 1999 201 221
105. A.D. Dergunov, A.S. Kaprel'iants, and D.N. Ostrovskii Changes in the structural state of boundary lipids in bacterial membrane under effect of the membranotropic antibiotic gramicidin S Biokhimiia 46 1981 1499 1509
106. R.C. Goldman, and F. Scaglione The macrolide-bacterium interaction and its biological basis Curr Drug Targets Infect Disord 4 2004 241 260
107. J.O. Capobianco, D. Zakula, M.L. Coen, and R.C. Goldman Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action Biochem Biophys Res Commun 190 1993 1037 1044 10.1006/bbrc.1993.1153
108. F. Bardou, C. Raynaud, C. Ramos, M.A. Laneelle, and G. Laneelle Mechanism of isoniazid uptake in Mycobacterium tuberculosis Microbiology 144 Pt 9 1998 2539 2544
109. L.J. Piddock, K.J. Williams, and V. Ricci Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis J Antimicrobial Chemother 45 2000 159 165
110. K.J. Williams, and L.J. Piddock Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus J Antimicrobial Chemother 42 1998 597 603
111. K.J. Williams, G.A. Chung, and L.J. Piddock Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis Antimicrobial Agents Chemother 42 1998 795 800
112. S. Corti, J. Chevalier, and A. Cremieux Intracellular accumulation of norfloxacin in Mycobacterium smegmatis Antimicrobial Agents Chemother 39 1995 2466 2471
113. W.H. Beggs, and N.E. Auran Uptake and binding of 14C-ethambutol by tubercle bacilli and the relation of binding to growth inhibition Antimicrobial Agents Chemother 2 1972 390 394
114. R.J. Wargel, C.A. Shadur, and F.C. Neuhaus Mechanism of D-cycloserine action: transport systems for D-alanine, D-cycloserine, L-alanine, and glycine J Bacteriol 103 1970 778 788
115. B.D. Davis Mechanism of bactericidal action of aminoglycosides Microbiol Rev 51 1987 341 350
116. B.D. Davis, L.L. Chen, and P.C. Tai Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides Proc Natl Acad Sci USA 83 1986 6164 6168
117. R. Goude, A.G. Amin, D. Chatterjee, and T. Parish The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis Antimicrobial Agents Chemother 53 2009 4138 4146 10.1128/AAC.00162-09
118. C. Plinke, H.S. Cox, N. Zarkua, H.A. Karimovich, K. Braker, and R. Diel embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation J Antimicrobial Chemother 65 2010 1359 1367 10.1093/jac/dkq120
119. C. Plinke, K. Walter, S. Aly, S. Ehlers, and S. Niemann Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo Antimicrobial Agents Chemother 55 2011 2891 2896 10.1128/AAC.00007-10
120. C. Raynaud, M.A. Laneelle, R.H. Senaratne, P. Draper, G. Laneelle, and M. Daffe Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity Microbiology 145 Pt 6 1999 1359 1367
121. H.I. Boshoff, V. Mizrahi, and C.E. Barry III Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I J Bacteriol 184 2002 2167 2172
122. L.B. Heifets, M.A. Flory, and P.J. Lindholm-Levy Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? Antimicrobial Agents Chemother 33 1989 1252 1254
123. P. Lu, A.C. Haagsma, H. Pham, J.J. Maaskant, S. Mol, and H. Lill Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels Antimicrobial Agents Chemother 55 2011 5354 5357 10.1128/AAC.00507-11
124. S.C. Ngo, O. Zimhony, W.J. Chung, H. Sayahi, W.R. Jacobs Jr., and J.T. Welch Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs Antimicrobial Agents Chemother 51 2007 2430 2435 10.1128/AAC.01458-06
125. W. Shi, X. Zhang, X. Jiang, H. Yuan, J.S. Lee, and C.E. Barry III Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis Science 333 2011 1630 1632 10.1126/science.1208813
126. R.J. Speirs, J.T. Welch, and M.H. Cynamon Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide Antimicrobial Agents Chemother 39 1995 1269 1271
127. O. Zimhony, C. Vilcheze, M. Arai, J.T. Welch, and W.R. Jacobs Jr. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli Antimicrobial Agents Chemother 51 2007 752 754 10.1128/AAC.01369-06
128. K.A. Brown, and C. Ratledge The effect of p-aminosalicyclic acid on iron transport and assimilation in mycobacteria Biochim et Biophys Acta 385 1975 207 220
129. S. Chakraborty, T. Gruber, C.E. Barry III, H.I. Boshoff, and K.Y. Rhee Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis Science 339 2013 88 91 10.1126/science.1228980
130. L. Favrot, and D.R. Ronning Targeting the mycobacterial envelope for tuberculosis drug development Expert Rev Anti-Infect Ther 10 2012 1023 1036 10.1586/eri.12.91
131. M. Niederweis, O. Danilchanka, J. Huff, C. Hoffmann, and H. Engelhardt Mycobacterial outer membranes: in search of proteins Trends Microbiol 18 2010 109 116 10.1016/j.tim.2009.12.005
132. P.J. Brennan, and H. Nikaido The envelope of mycobacteria Ann Rev Biochem 64 1995 29 63 10.1146/annurev.bi.64.070195.000333
133. B. Kartmann, S. Stenger, and M. Niederweis Porins in the cell wall of Mycobacterium tuberculosis J Bacteriol 181 1999 6543 6546
134. M. Niederweis Mycobacterial porins-new channel proteins in unique outer membranes Mol Microbiol 49 2003 1167 1177
135. M. Niederweis Nutrient acquisition by mycobacteria Microbiology 154 2008 679 692 10.1099/mic.0.2007/012872-0
136. C. Raynaud, K.G. Papavinasasundaram, R.A. Speight, B. Springer, P. Sander, and E.C. Bottger The functions of OmpATb, a pore-forming protein of Mycobacterium tuberculosis Mol Microbiol 46 2002 191 201
137. N. Mah, C. Perez-Iratxeta, and M.A. Andrade-Navarro Outer membrane pore protein prediction in mycobacteria using genomic comparison Microbiology 156 2010 2506 2515 10.1099/mic.0.040089-0
138. F. Doucet-Populaire, J.O. Capobianco, D. Zakula, V. Jarlier, and R.C. Goldman Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis J Antimicrobial Chemother 41 1998 179 187
139. H. Ouellet, L.M. Podust, and P.R. de Montellano Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs J Biol Chem 283 2008 5069 5080 10.1074/jbc.M708734200
140. L.M. Podust, H. Ouellet, J.P. von Kries, and P.R. de Montellano Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines J Biol Chem 284 2009 25211 25219 10.1074/jbc.M109.017632
141. H.E. Seward, A. Roujeinikova, K.J. McLean, A.W. Munro, and D. Leys Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode J Biol Chem 281 2006 39437 39443 10.1074/jbc.M607665200
142. S. Kim, S.N. Cho, T. Oh, and P. Kim Design and synthesis of 1H-1,2,3-triazoles derived from econazole as antitubercular agents Bioorg Med Chem Lett 22 2012 6844 6847 10.1016/j.bmcl.2012.09.041
143. S.H. Lee, S. Kim, M.H. Yun, Y.S. Lee, S.N. Cho, and T. Oh Synthesis and antitubercular activity of monocyclic nitroimidazoles: insights from econazole Bioorg Med Chem Lett 21 2011 1515 1518 10.1016/j.bmcl.2010.12.128
144. R.J. Naik, M.V. Kulkarni, K. Sreedhara Ranganath Pai, and P.G. Nayak Click chemistry approach for bis-chromenyl triazole hybrids and their antitubercular activity Chem Biol Drug Des 80 2012 516 523 10.1111/j.1747-0285. 2012.01441.x
145. S.T. Byrne, S.M. Denkin, P. Gu, E. Nuermberger, and Y. Zhang Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model J Med Microbiol 56 2007 1047 1051 10.1099/jmm.0.47058-0
146. L.E. Bermudez, P. Kolonoski, M. Wu, P.A. Aralar, and C.B. Inderlied Mefloquine is active in vitro and in vivo against Mycobacterium avium complex Antimicrobial Agents Chemother 43 1999 1870 1874
147. L. Danelishvili, M. Wu, L.S. Young, and L.E. Bermudez Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria Antimicrobial Agents Chemother 49 2005 3707 3714 10.1128/AAC.49.9.3707-3714.2005
148. I.L. Bergval, A.R. Schuitema, P.R. Klatser, and R.M. Anthony Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance J Antimicrobial Chemother 64 2009 515 523 10.1093/jac/dkp237
149. C.K. Stover, P. Warrener, D.R. VanDevanter, D.R. Sherman, T.M. Arain, and M.H. Langhorne A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 405 2000 962 966 10.1038/35016103
150. S. Ekins, J. Bradford, K. Dole, A. Spektor, K. Gregory, and D. Blondeau A collaborative database and computational models for tuberculosis drug discovery Mol BioSystems 6 2010 840 851 10.1039/b917766c
151. S. Ekins, T. Kaneko, C.A. Lipinski, J. Bradford, K. Dole, and A. Spektor Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis Mol BioSystems 6 2010 2316 2324 10.1039/c0mb00104j
152. M.Q. Zhang, and B. Wilkinson Drug discovery beyond the 'rule-of-five' Curr Opin Biotechnol 18 2007 478 488 10.1016/j.copbio.2007.10.005
153. P. Ertl, and A. Schuffenhauer Cheminformatics analysis of natural products: lessons from nature inspiring the design of new drugs Prog Drug Res Fortschritte der Arzneimittelforschung Progres des recherches pharmaceutiques 66 217 2008 219 235
154. M. Feher, and J.M. Schmidt Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry J Chem Inform Comput Sci 43 2003 218 227 10.1021/ci0200467
155. M.L. Lee, and G. Schneider Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries J Comb Chem 3 2001 284 289
156. N. Singh, R. Guha, M.A. Giulianotti, C. Pinilla, R.A. Houghten, and J.L. Medina-Franco Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository J Chem Inf Model 49 2009 1010 1024 10.1021/ci800426u
157. T. Fichert, M. Yazdanian, and J.R. Proudfoot A structure-permeability study of small drug-like molecules Bioorg Med Chem Lett 13 2003 719 722
158. T.H. Keller, A. Pichota, and Z. Yin A practical view of 'druggability' Curr Opin Chem Biol 10 2006 357 361 10.1016/j.cbpa.2006.06.014
159. M.S. Lajiness, M. Vieth, and J. Erickson Molecular properties that influence oral drug-like behavior Curr Opin Drug Discov Develop 7 2004 470 477
160. I. Muegge Selection criteria for drug-like compounds Med Res Rev 23 2003 302 321 10.1002/med.10041
161. D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple Molecular properties that influence the oral bioavailability of drug candidates J Med Chem 45 2002 2615 2623
162. M.C. Wenlock, R.P. Austin, P. Barton, A.M. Davis, and P.D. Leeson A comparison of physiochemical property profiles of development and marketed oral drugs J Med Chem 46 2003 1250 1256 10.1021/jm021053p
163. W.P. Walters Going further than Lipinski's rule in drug design Expert Opin Drug Discov 7 2012 99 107 10.1517/17460441.2012.648612
164. C. Abad-Zapatero, and D. Blasie Ligand efficiency indices (LEIs): more than a Simple efficiency Yardstick Mol Inform 30 2011 122 132
165. C. Abad-Zapatero, O. Perisic, J. Wass, A.P. Bento, J. Overington, and B. Al-Lazikani Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation Drug Discov Today 15 2010 804 811 10.1016/j.drudis.2010.08.004
166. A. Cortes-Cabrera, A. Morreale, F. Gago, and C. Abad-Zapatero AtlasCBS: a web server to map and explore chemico-biological space J Comput-Aided Mol Des 26 2012 995 1003 10.1007/s10822-012-9587-5
167. C. Abad-Zapatero A sorcerer's apprentice and the Rule of Five: from rule-of-thumb to commandment and beyond Drug Discov Today 12 2007 995 997 10.1016/j.drudis.2007.10.022
168. J.R. Platt Strong Inference: certain systematic methods of scientific thinking may produce much more rapid progress than others Science 146 1964 347 353 10.1126/science.146.3642.347
169. J. Baell, M. Congreve, P. Leeson, and C. Abad-Zapatero Ask the experts: past, present and future of the rule of five Future Med Chem 5 2013 745 752 10.4155/fmc.13.61
170. C. Lipinski Chris Lipinski. Interview by Peter Kirkpatrick Nat Rev Drug Discov 11 2012 900 901 10.1038/nrd3895
171. C.A. Lipinski Chris Lipinski discusses life and chemistry after the Rule of Five Drug Discov Today 8 2003 12 16
172. B.E. Eaton, L. Gold, and D.A. Zichi Let's get specific: the relationship between specificity and affinity Chem Biol 2 1995 633 638
173. R.C. Goldman, E.R. Baizman, C.B. Longley, and A.A. Branstrom Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding FEMS Microbiol Lett 183 2000 209 214
174. A.Y. Pavlov, O.V. Miroshnikova, S.S. Printsevskaya, E.N. Olsufyeva, M.N. Preobrazhenskaya, and R.C. Goldman Synthesis of hydrophobic N'-mono and N', N-double alkylated eremomycins inhibiting the transglycosylation stage of bacterial cell wall biosynthesis J Antibiot 54 2001 455 459
175. S.S. Printsevskaya, A.Y. Pavlov, E.N. Olsufyeva, E.P. Mirchink, E.B. Isakova, and M.I. Reznikova Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D- leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria J Med Chem 45 2002 1340 1347
176. U.S. Eggert, N. Ruiz, B.V. Falcone, A.A. Branstrom, R.C. Goldman, and T.J. Silhavy Genetic basis for activity differences between vancomycin and glycolipid derivatives of vancomycin Science 294 2001 361 364 10.1126/science.1063611
177. R.C. Page, S. Lee, J.D. Moore, S.J. Opella, and T.A. Cross Backbone structure of a small helical integral membrane protein: a unique structural characterization Protein Sci Pub Protein Soc 18 2009 134 146 10.1002/pro.24
178. J. Hu, M. Sharma, H. Qin, F.P. Gao, and T.A. Cross Ligand binding in the conserved interhelical loop of CorA, a magnesium transporter from Mycobacterium tuberculosis J Biol Chem 284 2009 15619 15628 10.1074/jbc.M901581200
179. H. Qin, J. Hu, Y. Hua, S.V. Challa, T.A. Cross, and F.P. Gao Construction of a series of vectors for high throughput cloning and expression screening of membrane proteins from Mycobacterium tuberculosis BMC Biotechnol 8 2008 51 10.1186/1472-6750-8-51
180. H.B. Nguyen, and T.A. Cross 1H, 15N and 13C backbone resonance assignment of Rv1567c, an integral membrane protein from Mycobacterium tuberculosis Biomol NMR Assign 2 2008 47 49 10.1007/s12104-008-9081-0
181. C. Li, P. Gao, H. Qin, R. Chase, P.L. Gor'kov, and W.W. Brey Uniformly aligned full-length membrane proteins in liquid crystalline bilayers for structural characterization J Am Chem Soc 129 2007 5304 5305 10.1021/ja068402f
182. A. Korepanova, J.D. Moore, H.B. Nguyen, Y. Hua, T.A. Cross, and F. Gao Expression of membrane proteins from Mycobacterium tuberculosis in Escherichia coli as fusions with maltose binding protein Protein Expr Purif 53 2007 24 30 10.1016/j.pep.2006.11.022
183. J. Hu, H. Qin, C. Li, M. Sharma, T.A. Cross, and F.P. Gao Structural biology of transmembrane domains: efficient production and characterization of transmembrane peptides by NMR Protein Sci Pub Protein Soc 16 2007 2153 2165 10.1110/ps.072996707
184. Y. Xiong, M.J. Chalmers, F.P. Gao, T.A. Cross, and A.G. Marshall Identification of Mycobacterium tuberculosis H37Rv integral membrane proteins by one-dimensional gel electrophoresis and liquid chromatography electrospray ionization tandem mass spectrometry J Proteome Res 4 2005 855 861 10.1021/pr0500049
185. A. Korepanova, F.P. Gao, Y. Hua, H. Qin, R.K. Nakamoto, and T.A. Cross Cloning and expression of multiple integral membrane proteins from Mycobacterium tuberculosis in Escherichia coli Protein Sci Pub Protein Soc 14 2005 148 158 10.1110/ps.041022305
186. C. Vilhena, and A. Bettencourt Daptomycin: a review of properties, clinical use, drug delivery and resistance Mini Rev Med Chem 12 2012 202 209
187. L.D. Saravolatz, G.E. Stein, and L.B. Johnson Telavancin: a novel lipoglycopeptide Clin Infect Dis Off Pub of the Infect Dis Soc Am 49 2009 1908 1914 10.1086/648438
188. B.E. Cohen Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects J Membr Biol 238 2010 1 20 10.1007/s00232-010-9313-y
189. M. Barcia-Macay, F. Mouaden, M.P. Mingeot-Leclercq, P.M. Tulkens, and F. Van Bambeke Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts) J Antimicrobial Chemother 61 2008 1288 1294 10.1093/jac/dkn120
190. F. Van Bambeke, J. Saffran, M.P. Mingeot-Leclercq, and P.M. Tulkens Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation Antimicrobial Agents Chemother 49 2005 1695 1700 10.1128/AAC.49.5.1695-1700.2005
191. P.M. Hawkey Pre-clinical experience with daptomycin J Antimicrobial Chemother 62 Suppl. 3 2008 iii7 14 10.1093/jac/dkn367
192. J.O. Capobianco, D. Zakula, D.J. Frost, R.C. Goldman, L. Li, and L.L. Klein Cellular accumulation, localization, and activity of a synthetic cyclopeptamine in fungi Antimicrobial Agents Chemother 42 1998 389 393
193. F. Wang, D. Sambandan, R. Halder, J. Wang, S.M. Batt, B. Weinrick, I. Ahmad, P. Yang, Y. Zhang, J. Kim, M. Hassani, S. Huszar, C. Trefzer, Z. Ma, T. Kaneko, K.E. Mdluli, S. Franzblau, A.K. Chatterjee, K. Johnson, K. Mikusova, G.S. Besra, K. Futterer, W.R. Jacobs, and P.G. Schultz Identification of a small molecule with activity against drug-resistant and persistent tuberculosis Proc Natl Acad Sci USA 110 2013 E2510 E2517 10.1073/pnas.1309171110